

Lucesca SE
Form 4
November 20, 2017

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
JAB Cosmetics B.V.

2. Issuer Name and Ticker or Trading Symbol
COTY INC. [COTY]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

OOSTERDOKSSTRAAT 80,

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2017

____ Director 10% Owner
____ Officer (give title below) ____ Other (specify below)

(Street)

4. If Amendment, Date Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

AMSTERDAM, P7 NL 1011 DK

____ Form filed by One Reporting Person
 Form filed by More than One Reporting Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Ownership (Instr. 4) |
|--|--------------------------------------|--|--------------------------------|---|---|--|--|
| | | | Code | V | Amount | (A) or (D) | Price |
| Class A Common Stock, par value \$0.01 per share | 11/16/2017 | | P | | 1,800,000 (1) | A | \$ 16.8426 (2) |
| Class A Common Stock, par value \$0.01 per share | 11/17/2017 | | P | | 1,000,000 (1) | A | \$ 17.1082 (3) |

Edgar Filing: Lucesca SE - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 5) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| JAB Cosmetics B.V. OOSTERDOKSSTRAAT 80 AMSTERDAM, P7 NL 1011 DK | | X | | |
| Agnaten SE ROOSEVELTPLATZ 4-5 TOP 10 VIENNA, C4 A-1090 | | X | | |
| Lucesca SE ROOSEVELTPLATZ 4-5 TOP 10 VIENNA, C4 A-1090 | | X | | |
| JAB Holdings B.V. OOSTERDOKSSTRAAT 80 AMSTERDAM, P7 NL 1011 DK | | X | | |

Signatures

/s/ Joachim Creus and /s/ Markus Hopmann as Managing Directors 11/20/2017

Signature of Reporting Person

Date

/s/ Joachim Creus and /s/ Markus Hopmann as Authorized Representatives 11/20/2017

Edgar Filing: Lucreca SE - Form 4

| <u> </u> **Signature of Reporting Person | Date |
|--|------------|
| /s/ Constantin Thun-Hohenstein and /s/ Dietmar Guetter as Authorized Representatives | 11/20/2017 |

| <u> </u> **Signature of Reporting Person | Date |
|--|------------|
| /s/ Joachim Creus and /s/ Markus Hopmann as Managing Directors | 11/20/2017 |

| <u> </u> **Signature of Reporting Person | Date |
|---|------|
|---|------|

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Purchases made in open market transactions in accordance with Rule 10b-18 of the Securities Exchange Act of 1934, as amended.
The shares were purchased in multiple transactions on November 16, 2017 at actual purchase prices ranging from \$16.73 to \$17.02 per share, exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- (2) The shares were purchased in multiple transactions on November 17, 2017 at actual purchase prices ranging from \$16.87 to \$17.14 per share, exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- (3) The shares were purchased in multiple transactions on November 17, 2017 at actual purchase prices ranging from \$16.87 to \$17.14 per share, exclusive of any fees, commissions or other expenses. The price reported reflects the weighted average purchase price for the transactions. The Reporting Persons undertake to provide upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.